A Phase II, Randomized, Double-Blind, Randomized, Active-Controlled Study to Assess the Safety and Efficacy of NBI-56418 in Subjects With Endometriosis.

Trial Profile

A Phase II, Randomized, Double-Blind, Randomized, Active-Controlled Study to Assess the Safety and Efficacy of NBI-56418 in Subjects With Endometriosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2014

At a glance

  • Drugs Elagolix (Primary) ; Medroxyprogesterone
  • Indications Endometriosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PETAL
  • Sponsors AbbVie
  • Most Recent Events

    • 20 Feb 2012 Abbott as trial company, lead trial centre and lead trial investigator (Williams L) added as reported by ClinicalTrials.gov.
    • 21 Oct 2009 Efficacy and tolerability results reported at the 65th Annual Meeting of the American Society for Reproductive Medicine.
    • 06 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top